Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
WRAL Documentary Easy Targets: Gangs getting younger in NC
Recommended
Hurricane season 2024: Beware rip current danger if you visit NC coast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altamira Therapeutics Ltd
(NQ:
CYTO
)
1.240
+0.030 (+2.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Altamira Therapeutics Ltd
< Previous
1
2
3
4
Next >
Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant
November 12, 2021
- Significant reduction of infectious viral titer in human nasal epithelium model with either prophylactic or therapeutic application - Results provide further confirmation for broad applicability in...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Altamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets
October 25, 2021
HAMILTON, BERMUDA / ACCESSWIRE / October 25, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application
October 14, 2021
HAMILTON, BERMUDA / ACCESSWIRE / October 14, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Product Safety
Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference
October 06, 2021
HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Provides Update on Bentrio Program
September 27, 2021
- Building Bentrio™ brand and expanding in European markets - 510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA") - Distributors signed up...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program
September 21, 2021
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
September 08, 2021
- Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 - Enrollment in Phase 2 trial of AM-125...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
August 06, 2021
- Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) - New data demonstrate protective effects in viral infections...
From
Altamira Therapeutics
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
Death
Intellectual Property
Legal
Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
August 03, 2021
HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.